INT19844

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 12
Total Number 15
Disease Relevance 3.19
Pain Relevance 2.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
plasma 4
pituitary 4
peptidergic neurons 2
theca cells 2
Lhb (Mus musculus)
Pain Link Frequency Relevance Heat
narcan 33 99.98 Very High Very High Very High
Endogenous opioid 5 99.78 Very High Very High Very High
agonist 44 96.60 Very High Very High Very High
Dopamine 46 96.24 Very High Very High Very High
Neurotransmitter 8 83.88 Quite High
Enkephalin 2 76.04 Quite High
antagonist 16 75.00 Quite High
Opioid 3 75.00 Quite High
cva 29 74.56 Quite High
opiate 3 74.56 Quite High
Disease Link Frequency Relevance Heat
Endometriosis (extended) 52 99.60 Very High Very High Very High
Hirsutism 13 94.04 High High
Breast Cancer 196 90.40 High High
Immunotherapy Of Cancer 20 86.80 High High
Disease 27 86.48 High High
Nutritional Deficiencies 1 85.08 High High
Postmenopausal Osteoporosis 4 82.48 Quite High
Advanced Or Metastatic Breast Cancer 28 81.28 Quite High
Osteoporosis 24 76.64 Quite High
Reprotox - General 1 23 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Alternatively, release of endogenous opioids in association with increasing feed intake or other lactational hormone responses may provide neural or pituitary inhibition of the pulsatile LH production that is requisite for ovarian follicular development.
Negative_regulation (inhibition) of Gene_expression (production) of LH in pituitary associated with endogenous opioid
1) Confidence 0.51 Published 1989 Journal J. Dairy Sci. Section Abstract Doc Link 2654227 Disease Relevance 0.09 Pain Relevance 0.10
These data suggest that endogenous opioids tonically suppress frequency- and amplitude-dependent neuromodulation of LH production, probably through hypothalamic mechanisms that impinge upon gonadotropin-releasing hormone-secreting peptidergic neurons.
Negative_regulation (suppress) of Gene_expression (production) of LH in peptidergic neurons associated with endogenous opioid
2) Confidence 0.41 Published 1982 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 7061693 Disease Relevance 0 Pain Relevance 0.32
Naloxone induced a significant (P less than 0.01) decrease in LH concentrations in females 10 to 60 min after injection (saline: 2.3 +/- 0.2 ng/ml plasma (SEM); 0.5 mg naloxone/kg: 1.0 +/- 0.2 ng/ml plasma and 2 mg naloxone/kg 1.2 +/- 0.4 ng/ml plasma).
Negative_regulation (decrease) of Gene_expression (concentrations) of LH in plasma associated with narcan
3) Confidence 0.40 Published 1990 Journal J. Dev. Physiol. Section Abstract Doc Link 2099379 Disease Relevance 0.07 Pain Relevance 0.55
In males low doses of naloxone reduced plasma LH levels 10 to 40 min after injection (saline: 2.0 +/- 0.3 ng/ml plasma and 0.5 ng naloxone/kg: 1.1 +/- 0.3 ng/ml), whereas a decrease in plasma LH levels occurred 80 to 140 min after injection of high doses of naloxone (saline: 2.1 +/- 0.2 ng/ml and 2 mg naloxone/kg: 1.0 +/- 0.2 ng/ml).
Negative_regulation (reduced) of Gene_expression (levels) of LH in plasma associated with narcan
4) Confidence 0.40 Published 1990 Journal J. Dev. Physiol. Section Abstract Doc Link 2099379 Disease Relevance 0.06 Pain Relevance 0.57
Pretreatment with CRF antiserum prevented the decrease in LH levels seen during NMA (45 mg) in 4 of 8 monkeys (hour 2, -8.5% (+/- 6.5); hour 3, -10.3% (+/- 4.3); P less than 0.01 vs.
Negative_regulation (decrease) of Gene_expression (levels) of LH
5) Confidence 0.24 Published 1990 Journal Endocrinology Section Abstract Doc Link 2197080 Disease Relevance 0 Pain Relevance 0.15
Although interpretation was limited by the small sample size, arzoxifene appeared to lower proliferation markers including proliferating cell nuclear antigen (PCNA), insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3), decrease estrogen expression and LH levels, and increase SHBG levels.
Negative_regulation (decrease) of Gene_expression (expression) of LH
6) Confidence 0.17 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012444 Disease Relevance 1.10 Pain Relevance 0.13
In terms of hormone and bone biomarkers, the European trial showed a significant decrease in FSH and estradiol levels in postmenopausal women, and a significant increase in SHBG levels for both arzoxifene doses, with a significant decrease in LH levels for the 50 mg/day dose only (Baselga et al. 2003), although there was no significant difference between the two dosages.
Negative_regulation (decrease) of Gene_expression (levels) of LH
7) Confidence 0.13 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012444 Disease Relevance 0.21 Pain Relevance 0
The American trial did not show these changes overall, although when analyzed according to menopausal status there was a decrease in FSH and LH levels, and an increase in SHBG level in post-menopausal women.
Negative_regulation (decrease) of Gene_expression (levels) of LH associated with endometriosis (extended)
8) Confidence 0.13 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012444 Disease Relevance 0.49 Pain Relevance 0.05
In both phase I and II studies arzoxifene showed similar endocrine effects of decreasing FSH and LH levels with increasing SHBG levels as had been reported with tamoxifen (L√łnning et al. 1995; Kostoglou-Athanassiou et al. 1997).
Negative_regulation (decreasing) of Gene_expression (levels) of LH
9) Confidence 0.13 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012444 Disease Relevance 0.55 Pain Relevance 0.08
This effect of LH was not inhibited by PGF2?
Negative_regulation (inhibited) of Gene_expression (effect) of LH
10) Confidence 0.12 Published 2007 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2041951 Disease Relevance 0 Pain Relevance 0.12
This effect of LH was completely inhibited by PGF2?
Negative_regulation (inhibited) of Gene_expression (effect) of LH
11) Confidence 0.12 Published 2007 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2041951 Disease Relevance 0 Pain Relevance 0
LHRH analogues (e.g., leuprolide acetate) desensitise and downregulate pituitary LHRH receptors, thus reducing LH synthesis and release.
Negative_regulation (reducing) of Gene_expression (synthesis) of LH in pituitary
12) Confidence 0.08 Published 2004 Journal Expert Opin Pharmacother Section Abstract Doc Link 14996640 Disease Relevance 0.38 Pain Relevance 0.10
As compared to saline and naloxone alone, LH pulse frequency was significantly decreased by AVP (p < 0.05) and by 5 h, the mean LH expressed as a percentage from the 3-hour baseline was also significantly reduced (saline 100.9 +/- 5.1%; naloxone 112.3 +/- 2.9%; AVP 63.3 +/- 8.2%).
Negative_regulation (reduced) of Gene_expression (expressed) of LH associated with narcan
13) Confidence 0.08 Published 1996 Journal Neuroendocrinology Section Abstract Doc Link 8875440 Disease Relevance 0 Pain Relevance 0.52
Serum LH levels were reduced by 57% and 75% by SKF 38393 and LY 171555, respectively, indicating that the treatments produced physiologically relevant responses in vivo.
Negative_regulation (reduced) of Gene_expression (levels) of LH
14) Confidence 0.04 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2924890 Disease Relevance 0 Pain Relevance 0.27
As all progestins, it inhibits LH, and subsequently the production of androgens by the ovarian theca cells, and increases the hepatic clearance of testosterone.
Negative_regulation (inhibits) of Gene_expression (production) of LH in theca cells
15) Confidence 0.03 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504056 Disease Relevance 0.24 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox